New Evidence: The WID-easy Test Can Reduce NHS Costs
- Hannah Hunt
- 3 days ago
- 2 min read
Snowsill et al.; Cost-minimisation analysis of the WID-qEC epigenetic biomarker compared to transvaginal ultrasound for triaging abnormal uterine bleeding. Value in Health, 2026
A newly peer-reviewed cost-minimisation analysis published in Value in Health demonstrates that WID-easy offers a compelling economic and clinical alternative to transvaginal ultrasound (TVUS) as the first-line triage test for patients presenting with abnormal uterine bleeding (AUB) referred to the Urgent Suspected Cancer pathway.
Key Findings of the Cost Analysis
TVUS has a low specificity resulting in many unnecessary procedures, which are often invasive, painful and costly.
Utilising the data from the prospective, observational EPI-SURE study, a cost minimisation analysis was undertaken.
A decision tree model was created to simulate the costs associated with the current standard of care versus use of the WID-easy test from initial triage to definitive evaluation as part of the short term diagnostic pathway (Urgent Suspected Cancer pathway).
The model evaluated cost-savings associated with replacing TVUS with the WID-easy test and the subsequent reductions in unnecessary histology (Pipelle, OP hysteroscopy, GA hysteroscopy).
At a list price of £150.00, utilising the WID-easy test (UKCA version) would create a saving of £181.00 per patient that enters the pathway.
The mean breakeven price calculation indicated that if the test was sold at £302, the breakeven point would be met.
There is a >99% probability that using the WID-easy test would result in cost savings for the Urgent Suspected Cancer Pathway.
With urgent suspected gynaecological cancer referrals more than doubling over the past decade, NHS services are under growing pressure.
Evidence continues indicate that the WID-easy test may offer a range of benefits, including:
Reducing unnecessary hysteroscopies and biopsies
Minimising painful invasive procedures for patients
Increasing ultrasound capacity for other populations
Reducing waiting list pressures in overstretched gynaecology pathways
Clinical Value Beyond Cost of the WID-easy Test
In peer-reviewed research, WID-easy has demonstrated:
Equivalent sensitivity to TVUS for endometrial cancer detection 2,3
Higher specificity than TVUS 2,3
Much lower failure rates than ultrasound in routine triage settings 2,3
WID-easy offers fewer false positives, fewer inconclusive results, resulting in the potential for a more efficient pathway for triaging risk of endometrial cancer.
References
Snowsill et al., 2026
Evans et al. 2023. EPI-SURE
Ken-Amoah et al., IJC, 2024
